VectivBio: Funding, Investors & Team (Sep 2026)
VectivBio is a clinical-stage biotechnology organization carrying groundbreaking prescriptions to patients with serious interesting illnesses. They are focused on chasing after uncommon sicknesses with obvious science that can be designated with best-in-illness treatments that can possibly genuinely change and work on the existences of patients and their families, not simply give a gradual improvement or advantage over the norm of-care. It was established as a spinout from Therachon, a biotechnology organization procured by Pfizer for its program in achondroplasia. VectivBio was consolidated in 2019 and is situated in Basel, Switzerland.
VectivBio has raised $289M across 3 funding rounds on record, the most recent a Post-IPO Equity of $125M announced in Oct 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
VectivBio Company Profile and Key Stats
Latest funding round on record: Oct 2022.
VectivBio Funding Rounds
VectivBio raised $110M in an undisclosed round announced in Oct 2020.
1.7 years later, a Post-IPO Equity of $54.0M was announced in Jun 2022.
4 months later, a Post-IPO Equity of $125M was announced in Oct 2022.
VectivBio Founders and Leadership Team
Contact details for the VectivBio team: 1 of 1 has an email address on file.
Start 14-day free trial →VectivBio Funding Compared to Other Biotechnology Startups
VectivBio's latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like VectivBio in Biotechnology and Basel
Companies Similar to VectivBio
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
VectivBio Funding FAQs
What does VectivBio do?
VectivBio is a clinical-stage biotechnology organization carrying groundbreaking prescriptions to patients with serious interesting illnesses. They are focused on chasing after uncommon sicknesses with obvious science that can be designated with best-in-illness treatments that can possibly genuinely change and work on the existences of patients and their families, not simply give a gradual improvement or advantage over the norm of-care. It was established as a spinout from Therachon, a biotechnology organization procured by Pfizer for its program in achondroplasia. VectivBio was consolidated in 2019 and is situated in Basel, Switzerland.
How much funding has VectivBio raised?
VectivBio has raised $289M across 3 rounds on record. The most recent is a Post-IPO Equity of $125M announced in Oct 2022.
When did VectivBio last raise funding?
VectivBio's most recent funding round on record is a Post-IPO Equity of $125M, announced in Oct 2022.
Who is the CEO of VectivBio?
Luca Santarelli is listed as CEO at VectivBio.
Where is VectivBio headquartered?
VectivBio is based in Basel, Basel-Stadt, Switzerland.
How many employees does VectivBio have?
VectivBio is in the 51-100 employee band.
How does VectivBio's funding compare to other Biotechnology startups?
VectivBio's latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's VectivBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for VectivBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.